Stay updated on TMB & Neoantigen Relationship in Melanoma & Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the TMB & Neoantigen Relationship in Melanoma & Bladder Cancer Clinical Trial page.

Latest updates to the TMB & Neoantigen Relationship in Melanoma & Bladder Cancer Clinical Trial page
- Check5 days agoChange DetectedThe ClinicalTrials.gov page footer now identifies the site revision as v3.8.1 instead of v3.8.0.SummaryDifference0.1%

- Check12 days agoChange DetectedThe page presents the completed record for a Phase 2 study of nivolumab-based treatment in advanced melanoma and bladder cancer, including its study plan, eligibility criteria, outcome measures, locations, and linked protocol document.SummaryDifference56%

- Check19 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier changed from v3.7.2 to v3.8.0. The page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check33 days agoChange DetectedAn NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the 403 error page, and the displayed site revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check47 days agoChange DetectedThe footer’s site revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study content, making the trial record inaccessible; this blocks visibility of locations, investigators, and other essential details that the page normally presents to users.SummaryDifference19%

Stay in the know with updates to TMB & Neoantigen Relationship in Melanoma & Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TMB & Neoantigen Relationship in Melanoma & Bladder Cancer Clinical Trial page.